# Renal cell carcinoma

Source: https://onco.cc/key-papers/paper-hsieh-nat-rev-dis-primers/  
OnCo record `paper-hsieh-nat-rev-dis-primers` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one pathway page, indexed on Europe PMC as PubMed record 28276433 and published in Nature reviews. Disease primers; the citing page links this DOI, which is how the record was matched.

## Summary

Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. Although somatic VHL mutations have been described for some time, more-recent cancer genomic studies have identified mutations in epigenetic regulatory genes and demonstrated marked intra-tumour heterogeneity, which could have prognostic, predictive and therapeutic relevance. Localized RCC can be successfully managed with surgery, whereas metastatic RCC is refractory to conventional chemotherapy. However, over the past decade, marked advances in the treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, bevacizumab, pazopanib and axitinib, which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGFR), and everolimus and temsirolimus, which inhibit mechanistic target of rapamycin complex 1 (mTORC1), being approved. Since 2015, agents with additional targets aside from VEGFR have been approved, such as cabozantinib and lenvatinib; immunotherapies, such as nivolumab, have also been added to the armamentarium for metastatic RCC. Here, we provide an overview of the biology of RCC, with a focus on ccRCC, as well as updates to complement the current clinical guidelines and an outline of potential future directions for RCC research and therapy.

Indexed on Europe PMC as PubMed record 28276433 (DOI 10.1038/nrdp.2017.9). Matched by DOI alone: one pathway page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Nature reviews. Disease primers
- Year: 2017
- DOI: 10.1038/nrdp.2017.9
- Authors: Hsieh JJ, Purdue MP, Signoretti S, et al.
- What it means: One pathway page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Nat Rev Dis Primers 2017: https://doi.org/10.1038/nrdp.2017.9
- PubMed: https://pubmed.ncbi.nlm.nih.gov/28276433/
- Europe PMC: https://europepmc.org/article/MED/28276433

## Connected records

- pathways: [Renal cell carcinoma (KEGG map)](https://onco.cc/pathways/renal-cell-carcinoma-signalling/)

---
JSON: https://onco.cc/api/v1/entities/paper-hsieh-nat-rev-dis-primers.json